McKesson — Nov 5, 2025 release

• Adjusted Earnings per Diluted Share of $9.86 increased 39%. • Generated $2.4 billion of cash flow from operations and $2.2 billion of Free Cash Flow. Fiscal 2026 Full Year Outlook: • Raised Adjusted Earnings per Diluted Share guidance range to $38.35 to $38.85, from the previous range of $38.05 to $38.55. • Fiscal 2026 Adjusted Earnings per Diluted Share guidance range indicates 16% to 18% growth compared to the prior year. • The Company does not forecast GAAP earnings per diluted share 1 . "McKesson's second quarter results underscore the strength of our differentiated assets, capabilities, and continued momentum as a diversified healthcare services leader. We delivered record revenue in the quarter of $103 billion, increasing 10% and Adjusted Earnings per Diluted Share accelerating 39% compared to the prior year. These results reflect disciplined execution of our enterprise strategy - advancing growth in oncology and multispecialty and biopharma services. We remain confident in our ability to create value for our customers, partners, employees, and shareholders," said Brian Tyler, chief executive officer. "These achievements reflect the dedication of McKesson employees and their unwavering commitment to delivering measurable value to all stakeholders. Our strategic focus in our growth pillars of oncology and multispecialty and biopharma services, combined with disciplined execution, continues to drive sustainable long-term growth. Fol